9 research outputs found
A randomized, controlled trial of 3.0 mg of liraglutide in weight management
BACKGROUND Obesity is a chronic disease with serious health consequences, but weight loss is difficult to maintain through lifestyle intervention alone. Liraglutide, a glucagonlike peptide-1 analogue, has been shown to have potential benefit for weight management at a once-daily dose of 3.0 mg, injected subcutaneously. METHODS We conducted a 56-week, double-blind trial involving 3731 patients who did not have type 2 diabetes and who had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of at least 30 or a BMI of at least 27 if they had treated or untreated dyslipidemia or hypertension. We randomly assigned patients in a 2:1 ratio to receive once-daily subcutaneous injections of liraglutide at a dose of 3.0 mg (2487 patients) or placebo (1244 patients); both groups received counseling on lifestyle modification. The coprimary end points were the change in body weight and the proportions of patients losing at least 5% and more than 10% of their initial body weight. RESULTS At baseline, the mean (±SD) age of the patients was 45.1±12.0 years, the mean weight was 106.2±21.4 kg, and the mean BMI was 38.3±6.4; a total of 78.5% of the patients were women and 61.2% had prediabetes. At week 56, patients in the liraglutide group had lost a mean of 8.4±7.3 kg of body weight, and those in the placebo group had lost a mean of 2.8±6.5 kg (a difference of -5.6 kg; 95% confidence interval, -6.0 to -5.1; P<0.001, with last-observation-carried-forward imputation). A total of 63.2% of the patients in the liraglutide group as compared with 27.1% in the placebo group lost at least 5% of their body weight (P<0.001), and 33.1% and 10.6%, respectively, lost more than 10% of their body weight (P<0.001). The most frequently reported adverse events with liraglutide were mild or moderate nausea and diarrhea. Serious events occurred in 6.2% of the patients in the liraglutide group and in 5.0% of the patients in the placebo group. CONCLUSIONS In this study, 3.0 mg of liraglutide, as an adjunct to diet and exercise, was associated with reduced body weight and improved metabolic control. (Funded by Novo Nordisk; SCALE Obesity and Prediabetes NN8022-1839 ClinicalTrials.gov number, NCT01272219.)
Gamma-delta T-cell lymphomas.
Peripheral T-cell lymphomas (TCLs) are uncommon neoplasms, accounting for about 12% of all lymphoid tumors worldwide. TCLs in which \u3b3\u3b4 T-cell receptors are expressed (\u3b3\u3b4 TCLs) are extremely aggressive and rare (<1% of lymphoid neoplasms). \u3b3\u3b4 TCLs originate from \u3b3\u3b4 T cells, a small subset of peripheral T cells with direct antigen recognition capability acting at the interface between innate and adaptive immunity. Two distinct \u3b3\u3b4 TCL entities are recognized: hepatosplenic T-cell lymphoma (HSTL) and primary cutaneous \u3b3\u3b4 T-cell lymphoma (PCGD-TCL). HSTL is a well-characterized extranodal lymphoma that has a disguised onset, secondary to intrasinusoidal infiltration of the spleen, liver and bone marrow, has a rapidly progressive course that is poorly responsive to chemotherapy, and often ensues in the setting of immune system suppression. PCGD-TCL can present with prominent epidermal involvement or with a panniculitis-like clinical picture that can be complicated by a concurrent hemophagocytic syndrome; the disease shows biological and phenotypic overlap with other extranodal \u3b3\u3b4 TCLs that involve the respiratory or gastrointestinal tract mucosa. The regular application of phenotypic and molecular techniques is crucial for the diagnosis of \u3b3\u3b4 TCLs. In this Review, we discuss the clinical and biological features, the diagnostic challenges and the therapeutic perspectives of HSTL and PCGD-TCL
Mast cells acquisition of a predominant inflammatory over tolerogenic phenotype contributes to the development of autoimmune diabetes
High-performance metabolic marker assessment in breast cancer tissue by mass spectrometry
BACKGROUND: The identification of reliable markers for diagnosis of breast cancer has been thoroughly addressed by metabolic profiling using nuclear magnetic resonance (NMR) spectroscopy or imaging. Several clear diagnostic indicators have emerged using either in vitro analysis of tissue extracts, ex vivo analysis of biopsies or in vivo direct spectral observations. Most of the breast cancer characteristic metabolites could be assayed by mass spectrometry (MS) to exploit the superior sensitivity of this technique and therefore reduce the traumatic impact of current biopsy procedures.
METHODS: Following extraction, aqueous metabolite mixtures were obtained that were submitted to liquid-chromatography, electrospray-ionization, mass spectrometry (LC/ESI-MS) analysis to estimate the content of choline (Cho) and its phosphorylated derivatives, phosphocholine (PCho) and glycerophosphocholine (GPCho). The determinations were performed using 10 samples from breast tissue biopsies, surgical specimens and one single sample of a hepatic metastasis. In addition, some measurements were also repeated using high-resolution \ub9H NMR spectroscopy to complement the mass spectrometry results.
RESULTS: The contents of Cho, PCho and GPCho in breast tissue extracts were estimated by LC/ESI-MS based on standard compound calibration curves. Sharply increased ratios of phosphorylated-to-unphosphorylated metabolites, PCho/ Cho and (PCho+GPCho)/Cho, were observed in all tumor samples, although without discrimination between benign and malignant lesions, contrary to samples from healthy individuals and from those with fibrocystic disease.
CONCLUSIONS: The assessment of breast cancer markers by LC/ESI-MS is feasible and diagnostically valuable. In addition to high sensitivity, the approach also shows a resolution advantage for assaying choline derivatives compared to NMR, and could complement the latter
Oxidative Activity of Ammonium Persulfate Salt on Mast Cells and Basophils: Implication in Hairdressers’ Asthma
Monocyte adhesion to atherosclerotic matrix proteins is enhanced by Asn-Gly-Arg deamidation
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
BACKGROUND: Obesity is a chronic disease with serious health consequences, but
weight loss is difficult to maintain through lifestyle intervention alone.
Liraglutide, a glucagon-like peptide-1 analogue, has been shown to have potential
benefit for weight management at a once-daily dose of 3.0 mg, injected
subcutaneously.
METHODS: We conducted a 56-week, double-blind trial involving 3731 patients who
did not have type 2 diabetes and who had a body-mass index (BMI; the weight in
kilograms divided by the square of the height in meters) of at least 30 or a BMI
of at least 27 if they had treated or untreated dyslipidemia or hypertension. We
randomly assigned patients in a 2:1 ratio to receive once-daily subcutaneous
injections of liraglutide at a dose of 3.0 mg (2487 patients) or placebo (1244
patients); both groups received counseling on lifestyle modification. The
coprimary end points were the change in body weight and the proportions of
patients losing at least 5% and more than 10% of their initial body weight.
RESULTS: At baseline, the mean (±SD) age of the patients was 45.1±12.0 years, the
mean weight was 106.2±21.4 kg, and the mean BMI was 38.3±6.4; a total of 78.5% of
the patients were women and 61.2% had prediabetes. At week 56, patients in the
liraglutide group had lost a mean of 8.4±7.3 kg of body weight, and those in the
placebo group had lost a mean of 2.8±6.5 kg (a difference of -5.6 kg; 95%
confidence interval, -6.0 to -5.1; P<0.001, with last-observation-carried-forward
imputation). A total of 63.2% of the patients in the liraglutide group as
compared with 27.1% in the placebo group lost at least 5% of their body weight
(P<0.001), and 33.1% and 10.6%, respectively, lost more than 10% of their body
weight (P<0.001). The most frequently reported adverse events with liraglutide
were mild or moderate nausea and diarrhea. Serious events occurred in 6.2% of the
patients in the liraglutide group and in 5.0% of the patients in the placebo
group.
CONCLUSIONS: In this study, 3.0 mg of liraglutide, as an adjunct to diet and
exercise, was associated with reduced body weight and improved metabolic control.
(Funded by Novo Nordisk; SCALE Obesity and Prediabetes NN8022-1839
ClinicalTrials.gov number, NCT01272219.)